Skip to main content
GILD
NASDAQ Life Sciences

Gilead's Livdelzi Hits Primary Endpoint in Phase 3 PBC Trial with Strong Safety

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$130.94
Mkt Cap
$162.77B
52W Low
$104.46
52W High
$157.29
52W Position info
25% above low
Off High info
17% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

GILD sits 25% above its 52-week low of $104.46.

Summary

Gilead's Livdelzi (seladelpar) achieved statistically significant composite ALP normalization in its Phase 3 IDEAL trial for Primary Biliary Cholangitis (PBC). The drug also demonstrated a generally well-tolerated safety profile with no new concerns. This positive clinical data is a crucial step towards regulatory approval and commercialization, potentially adding a new revenue stream for Gilead. It also validates the company's ongoing investment in its pipeline, following recent strategic acquisitions.

At the time of this announcement, GILD was trading at $130.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.8B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GILD - Latest Insights

GILD
Nov 06, 2026, 12:16 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $167.82
Real-time Price: $170.00 info
Change: +$2.19 (+1%) info
Market Cap: $210.591B info
GILD
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $174.57
Real-time Price: $170.00 info
Change: -$4.56 (-3%) info
Market Cap: $210.591B info
GILD
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $165.88
Real-time Price: $170.00 info
Change: +$4.12 (+2%) info
Market Cap: $210.591B info
GILD
Oct 29, 2026, 4:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $164.00
Real-time Price: $170.00 info
Change: +$6.00 (+4%) info
Market Cap: $210.591B info
GILD
Oct 22, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $157.19
Real-time Price: $170.00 info
Change: +$12.81 (+8%) info
Market Cap: $210.591B info